Effect of Preemptive Midazolam on Post-Electroconvulsive-Therapy (ECT) Headache, Myalgia, and Nausea and Vomiting

Document Type : Original Article (s)

Authors

1 Assistant Professor, Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Sedigheh Tahereh Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Anesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Electroconvulsive therapy (ECT) is a controlled electrical stimulus that affects central nervous system and leads to convulsion. Such as every other medical procedure, electroconvulsive therapy has some side effects like headache, myalgia, and nausea and vomiting. Patient undergoing electroconvulsive therapy receives deferent anesthetic drugs and some drugs like Midazolam, Atropine etc. to reduce side effects.Methods: This study included 40 patients who were candidates for receiving electroconvulsive therapy. By using convenience sampling, patients were divided into 2 groups of 20 people. Midazolam were given to one group while the other received placebo. Two patients in midazolam group were removed because of short period of convulsion (lower than 20 seconds). The collected data were analyzed using independent t and chi-square tests.Findings: 16 men (42.1%) and 22 women (57.9%) were studied. The incidence of headache (P < 0.001), myalgia (P = 0.014) and vomiting (P = 0.011) was significantly higher in witness group. The incidence of coughing and laryngospasm was not significantly different between the two groups (P > 0.050).Conclusion: Midazolam can reduce convulsion time but in most cases, convulsions last more than 25 seconds, which is in therapeutic range. So, it cannot affect the therapeutic value of electroconvulsive therapy. Preemptive midazolam reduces Post-electroconvulsive-therapy headache, myalgia, and nausea.

Keywords

References

  1. Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. Miller's anesthesia. 8th ed. Philadelphia, PA: Saunders; 2014.
  2. Holden C. A guarded endorsement for shock therapy. Science 1985; 228(4707): 1510-1.
  3. Sadock BJ, Sadock VA. Brain stimulation methods. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007.
  4. Nuttall GA, Bowersox MR, Douglass SB, McDonald J, Rasmussen LJ, Decker PA, et al. Morbidity and mortality in the use of electroconvulsive therapy. J ECT 2004; 20(4): 237-41.
  5. Lyons JE, Symon J. Asystole during electroconvulsive therapy in an elderly woman treated concomitantly with venlafaxine. Aust N Z J Psychiatry 2008; 42(3): 255.
  6. American Psychiatric Association. The practice of electroconvulsive therapy recommendations for treatment, training and privileging. A task force report of the American Psychiatric Association. 2nd ed. Washington, DC: APA; 2001.
  7. White PF, Purdue L, Downing M, Thornton L. Intranasal sumatriptan for prevention of post-ECT headaches. Headache 2006; 46(4): 692.
  8. Logan CJ, Stewart JT. Treatment of post-electroconvulsive therapy headache with topical methyl salicylate. J ECT 2012; 28(2): e17-e18.
  9. Dinwiddie SH, Huo D, Gottlieb O. The course of myalgia and headache after electroconvulsive therapy. J ECT 2010; 26(2): 116-20.
  10. Ye L, Karlapati SK, Lippmann S. Topiramate for post-electroconvulsive therapy headaches. J ECT 2013; 29(3): e49.
  11. Palmio J, Huuhka M, Saransaari P, Oja SS, Peltola J, Leinonen E, et al. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res 2005; 137(3): 183-90.
  12. Millar K, Asbury AJ, Bowman AW, Hosey MT, Martin K, Musiello T, et al. A randomised placebo-controlled trial of the effects of midazolam premedication on children's postoperative cognition. Anaesthesia 2007; 62(9): 923-30.
  13. Sadock BJ, Sadock VA. Mood disorders. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007. p. 530.
  14. Yen T, Khafaja M, Lam N, Crumbacher J, Schrader R, Rask J, et al. Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial. J ECT 2015; 31(1): 20-5.
  15. Kheirabadi GR, Vafaie M, Attari A. Intravenous ketamine therapy vs. electroconvulsive therapy in depressive cases. J Isfahan Med Sch 2012; 29(163): 1975-83. [In Persian].
  16. Shah PJ, Dubey KP, Watti C, Lalwani J. Effectiveness of thiopentone, propofol and midazolam as an ideal intravenous anaesthetic agent for modified electroconvulsive therapy: A comparative study. Indian J Anaesth 2010; 54(4): 296-301.
  17. Weiner RD. The psychiatric use of electrically induced seizures. Am J Psychiatry 1979; 136(12): 1507-17.
Journal of Isfahan Medical School
Volume 35, Issue 417 - Serial Number 417
January and February 2017
Pages 26-31

Files

History

  • Receive Date: 03 October 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics